Despite recent therapeutic advances, pulmonary hypertension (PH) remains a fatal disease
due to the development of right ventricular (RV) failure. At present, no treatments targeted at …

Chronic thromboembolic pulmonary hypertension (CTEPH) is an underdiagnosed, but
potentially curable pulmonary vascular disease. The increased pulmonary vascular …

Background The evolution in pulmonary arterial hypertension (PAH) management has been
summarised in three iterations of the European Society of Cardiology/European Respiratory …

Pulmonary artery hypertension (PAH) pathology involves extracellular matrix (ECM)
remodeling in cardiac tissues, thus promoting cardiac fibrosis progression. miR-29a-3p …

Background Ventricular function, including left ventricular systolic dysfunction (LVSD), right
ventricular systolic dysfunction (RVSD), and biventricular dysfunction (BVD), contribute to …

Here we report application of human umbilical cord mesenchymal stem cell (HUCMSC)-
derived therapy for pulmonary arterial hypertension (PAH). A 3-year-old female presented …

Right ventricular failure (RVF) is often caused by increased afterload and disrupted coupling
between the right ventricle (RV) and the pulmonary arteries (PAs). After a phase of adaptive …

Pulmonary arterial hypertension (PAH) is a pulmonary vascular disease characterized by
pulmonary vascular remodeling and right heart enlargement the pathogenesis of PAH is …

BACKGROUND: Pathogenic concepts of right ventricular (RV) failure in pulmonary arterial
hypertension focus on a critical loss of microvasculature. However, the methods …

In response to various stressors, cardiac chambers undergo structural remodeling. Long-
term exposure of the right ventricle (RV) to pressure or volume overload leads to its …